Zynlonta manufacturer ADC Therapeutics is continuing to prune its pipeline, calling time on its sole clinical-stage candidate ...

The CD22-directed CAR-T, which was being tested in the FIRCE-1 study as a treatment for patients with relapsed/refractory large B-cell lymphoma (LBCL), was halted in January, with CARGO saying it ...

CAR-T cell therapy has revolutionized the treatment of relapsed and refractory B-acute lymphoblastic leukemia ... Researchers ...